Participation in activities of daily life can be challenging for those with ATTR-CM, a restrictive cardiomyopathy produced by extracellular deposition of transthyretin.
Videos On Demand
Recognize the Complexities of Transthyretin Amyloidosis (ATTR amyloidosis)
The clinical presentation of ATTR may be hidden in plain sight. In these continuing education activities explore the varied clinical presentations of amyloidosis in different organ systems including the heart, nervous system, gastro-intestinal tract, and kidneys. Get the facts from an expert panel on how to recognize and treat the complexities of this progressive, degenerative, and multisystemic disorder.
Extra-Cardiac Clues to Amyloidosis
This podcast will offer guidance on early identification of non-cardiac manifestations of amyloidosis from the perspective of the Gastrointestinal and Neurology clinical communities.
Future Directions and Areas of Uncertainty for ATTR: Where will we be in the next decade?
This podcast discusses areas of uncertainty and future directions in the screening, diagnosis, prognostic assessment, and management of ATTR Cardiac Amyloidosis. We will also discuss the effect of social determinants of health on access to effective diagnosis and treatment of ATTR Cardiac Amyloidosis and determine ways this can be improved. The podcast will also discuss gaps in knowledge about effective tools to follow disease progression in ATTR Cardiac Amyloidosis.
Unraveling the Mysteries of ATTR - Exploring Diagnostic Challenges, Laboratory Tests, Barriers, and Treatment Breakthroughs
Learn more in this podcast on the correct diagnosis of ATTR and how to devise a treatment plan for your patients. Experts will also discuss engaging in evaluative strategies for early detection through genetic testing by identifying genetic variants that are pertinent to the population we serve here in the United States especially that leads to hereditary ATTR.
Diagnostic Imaging Strategies for Cardiac Amyloidosis
This podcast will focus on multimodality cardiac imaging approaches and the application of diagnostic findings which contribute to an accurate diagnosis of ATTR-CM, specifically in differentiating ATTR-CA from AL-CA, and how to determine treatment options.
Pathophysiology and Clinical Features of TTR Cardiac Amyloidosis: No Longer a “Rare” Disease and Still Underdiagnosed
Health Care Practitioners (HCPs) have a pivotal role in ensuring the right patients get the right treatment. Patients living with ATTR-CM have new treatment options that have recently become available. In order to accurately diagnose and treat symptoms unique to the ATTR-CM patient, HCPs need to be aware of the application of guideline-based systematic, multimodal imaging and clinical diagnostics related to ATTR-CM. This podcast will highlight the latest terminology, treatments and guidelines for this no longer rare disease.
Pharmacotherapy for Cardiac Amyloidosis
In this podcast, experts will discuss the latest pharmacologic recommendations and their evolution in the treatment of cardiac amyloidosis. They will delineate the different potential therapeutic targets for the pharmacotherapy of cardiac amyloidosis including TTR silencing, stabilization, and disruption.
Resources for Clinicians
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging
Circulation: Cardiovascular Imaging
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2—Diagnostic Criteria and Appropriate Utilization
Circulation: Cardiovascular Imaging
This activity is supported by an independent educational grant from Pfizer.